GLUCOSE, ANHYDROUS
Head and Neck Squamous Cell Carcinoma
University College, LondonSmall moleculeN/ADormant
D
28/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 65/ 100
Competitive context
250 Active assets in the Head and Neck Squamous Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Akeso | Phase 4 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Akeso | Phase 3 | BB |
Irinotecan Neonc Technologies, Inc. | Phase 2 | BB |
Tisotumab Vedotin Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | BB |
Capecitabine Merck Sharp & Dohme LLC | Phase 2 | BB |
View all 50 →
Same molecule, other indications
GLUCOSE, ANHYDROUS is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →